| Paris, FRANCE, November 12, 2007 - 2007 Aureus Pharma, a leading provider of knowledge management solutions to accelerate discovery in the life sciences industry, today announced that Bristol-Myers Squibb Company (NYSE: BMY) has renewed its license to Aureus´ AurSCOPE GPCR, and has also licensed Aureus’ AurSCOPE Kinase and Ion Channel Knowledge databases.
Aureus Pharma´ s target-family-based AurSCOPE knowledge databases contain quantitative biological activity data which has been mined from the scientific literature. By understanding existing structure activity relationships, and the overall pharmacological space associated with a target/ligand, researchers can better design and prioritize experiments.
"We are very pleased that Bristol-Myers Squibb has chosen Aureus Pharma as a partner for knowledge based drug discovery," commented Jason Theodosiou, CEO of Aureus Pharma. "Bristol-Myers Squibb has been an important customer since 2002 and we regard their renewal and license extension as confirmation that our knowledge database solutions are meeting the needs of the world´s leading pharmaceutical companies."
About Aureus Pharma
Aureus Pharma headquartered in Paris, France is a privately held knowledge management based solutions provider for the life sciences industry. Aureus accelerates drug discovery by providing knowledge databases which contain high quality quantitative information for both chemistry and biology. Researchers gain rapid access to knowledge for important drug target classes including GPCR, Ion Channel, Kinase as well as other critical pharma topics including ADME/Drug-Drug Interactions and the hERG Channel. The data contained in the Aureus Pharma system is of importance to aid in lead discovery and optimization as well as to build predictive models. For further information on how Aureus helps researchers turn data into discovery visit www.aureus-pharma.com
Media Contact:
|
